302 related articles for article (PubMed ID: 25487791)
1. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Lodise TP; Anzueto AR; Weber DJ; Shorr AF; Yang M; Smith A; Zhao Q; Huang X; File TM
Antimicrob Agents Chemother; 2015 Feb; 59(2):1119-26. PubMed ID: 25487791
[TBL] [Abstract][Full Text] [Related]
2. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
[TBL] [Abstract][Full Text] [Related]
3. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
4. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
5. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
6. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley I; Thye D
Clin Infect Dis; 2010 Dec; 51(12):1395-405. PubMed ID: 21067350
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
DiMondi VP; Drew RH; Chen LF
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
[TBL] [Abstract][Full Text] [Related]
12. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
Blumer JL; Ghonghadze T; Cannavino C; O'Neal T; Jandourek A; Friedland HD; Bradley JS
Pediatr Infect Dis J; 2016 Jul; 35(7):760-6. PubMed ID: 27078119
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
14. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Welte T; Kantecki M; Stone GG; Hammond J
Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
[TBL] [Abstract][Full Text] [Related]
15. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
Shorr AF; Kollef M; Eckburg PB; Llorens L; Friedland HD
Diagn Microbiol Infect Dis; 2013 Mar; 75(3):298-303. PubMed ID: 23357290
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Scott LJ
Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
18. [Ceftaroline fosamil in community-acquired and nosocomial pneumonia].
Calbo E; Zaragoza R
Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():38-43. PubMed ID: 24702978
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain.
Torres A; Bassetti M; Welte T; Rivolo S; Remak E; Peral C; Charbonneau C; Hammond J; Ansari W; Grau S
J Med Econ; 2020 Feb; 23(2):148-155. PubMed ID: 31686550
[No Abstract] [Full Text] [Related]
20. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.
El Hajj MS; Turgeon RD; Wilby KJ
Int J Clin Pharm; 2017 Feb; 39(1):26-32. PubMed ID: 28058593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
